AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023 at 04:05 pm EDT
Share
AcelRx Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 4.37 million compared to net income of USD 63.15 million a year ago. Basic loss per share from continuing operations was USD 0.41 compared to basic earnings per share from continuing operations of USD 9.08 a year ago. Diluted loss per share from continuing operations was USD 0.41 compared to diluted earnings per share from continuing operations of USD 9.08 a year ago. Basic loss per share was USD 0.4 compared to basic earnings per share of USD 8.58 a year ago. Diluted loss per share was USD 0.4 compared to diluted earnings per share of USD 8.58 a year ago.
For the six months, net loss was USD 12.52 million compared to net income of USD 55.37 million a year ago. Basic loss per share from continuing operations was USD 0.4 compared to basic earnings per share from continuing operations of USD 8.62 a year ago. Diluted loss per share from continuing operations was USD 0.4 compared to diluted earnings per share from continuing operations of USD 8.62 a year ago. Basic loss per share was USD 1.15 compared to basic earnings per share of USD 7.56 a year ago. Diluted loss per share was USD 1.15 compared to diluted earnings per share of USD 7.56 a year ago.
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.